Provention Bio (NASDAQ:PRVB) posted its quarterly earnings results on Thursday. The company reported ($0.17) earnings per share for the quarter, Morningstar.com reports.

NASDAQ:PRVB traded down $0.02 during trading hours on Friday, hitting $3.16. 21,053 shares of the company’s stock traded hands, compared to its average volume of 51,935. Provention Bio has a twelve month low of $2.52 and a twelve month high of $8.00.

An institutional investor recently bought a new position in Provention Bio stock. Dean Capital Investments Management LLC purchased a new stake in shares of Provention Bio Inc (NASDAQ:PRVB) during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 40,950 shares of the company’s stock, valued at approximately $164,000. Dean Capital Investments Management LLC owned 0.12% of Provention Bio at the end of the most recent quarter.

TRADEMARK VIOLATION NOTICE: This story was first reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. & international trademark and copyright laws. The original version of this story can be viewed at https://theolympiareport.com/2018/11/10/provention-bio-prvb-announces-quarterly-earnings-results.html.

Provention Bio Company Profile

Provention Bio, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics and cutting-edge solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-6527, oral CSF-1R inhibitor, which is in Phase 2a clinical trial for the treatment of Crohn's disease; PRV-300, anti-TLR3 mAb, which is in Phase 1b clinical trial for the treatment of ulcerative colitis; PRV-3279 for the treatment of lupus; and PRV-101, a multivalent coxsackie virus vaccine for the prevention of acute Coxsackie Virus B Vaccine and the prevention of the onset of T1D.

Recommended Story: Find a Trading Strategy That Works

Receive News & Ratings for Provention Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Provention Bio and related companies with MarketBeat.com's FREE daily email newsletter.